Literature DB >> 18057086

Factors associated with a second hip fracture: a systematic review.

Mary Egan1, Susan Jaglal, Kerry Byrne, Jennie Wells, Paul Stolee.   

Abstract

OBJECTIVE: To provide a systematic review of factors associated with subsequent hip fracture among individuals who have fractured a hip. DATA SOURCES: We searched Ageline, CINAHL, EMBASE and MEDLINE, from database inceptions to the week of 5 June 2006. REVIEW
METHODS: Studies were selected if they provided information regarding risk of subsequent hip fracture among individuals who had fractured a hip. Study quality was assessed using the Jadad criteria for randomized controlled trials (RCTs) and a simple scale based on the MOOSE criteria for cohort studies.
RESULTS: Four RCTs and seven cohort studies were identified. Older age, cognitive impairment and lower bone mass appear to increase the risk of subsequent fracture, as did impaired depth perception, impaired mobility, previous falls, dizziness and poor or fair self-perceived health. Pharmacologic treatment for osteoporosis decreased the risk of subsequent fracture. Use of hip protectors by community-dwelling seniors did not appear to protect against a second fracture.
CONCLUSION: A number of easily observed risk factors may help identify those individuals at higher risk for subsequent fracture.

Entities:  

Mesh:

Year:  2007        PMID: 18057086     DOI: 10.1177/0269215507081573

Source DB:  PubMed          Journal:  Clin Rehabil        ISSN: 0269-2155            Impact factor:   3.477


  25 in total

1.  The future is physio ….

Authors:  Maureen C Ashe
Journal:  Physiother Can       Date:  2011-01-20       Impact factor: 1.037

2.  Exploring older adults' patterns and perceptions of exercise after hip fracture.

Authors:  Erin Gorman; Anna M Chudyk; Christiane A Hoppmann; Heather M Hanson; Pierre Guy; Joanie Sims-Gould; Maureen C Ashe
Journal:  Physiother Can       Date:  2013       Impact factor: 1.037

3.  Oral bisphosphonates are associated with reduced mortality after hip fracture.

Authors:  L A Beaupre; D W Morrish; D A Hanley; W P Maksymowych; N R Bell; A G Juby; S R Majumdar
Journal:  Osteoporos Int       Date:  2010-11-04       Impact factor: 4.507

4.  Comparing three machine learning approaches to design a risk assessment tool for future fractures: predicting a subsequent major osteoporotic fracture in fracture patients with osteopenia and osteoporosis.

Authors:  B C S de Vries; J H Hegeman; W Nijmeijer; J Geerdink; C Seifert; C G M Groothuis-Oudshoorn
Journal:  Osteoporos Int       Date:  2021-01-07       Impact factor: 4.507

Review 5.  Temporal trends in the incidence of osteoporotic fractures.

Authors:  S N Morin; L M Lix; S R Majumdar; W D Leslie
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

6.  A model for time to fracture with a shock stream superimposed on progressive degradation: the Study of Osteoporotic Fractures.

Authors:  Xin He; G A Whitmore; Geok Yan Loo; Marc C Hochberg; Mei-Ling Ting Lee
Journal:  Stat Med       Date:  2014-11-06       Impact factor: 2.373

7.  Incidence of second hip fracture and compliant use of bisphosphonate.

Authors:  Y-K Lee; Y-C Ha; B-H Yoon; K-H Koo
Journal:  Osteoporos Int       Date:  2012-12-18       Impact factor: 4.507

Review 8.  Management of osteoporosis among home health and long-term care patients with a prior fracture.

Authors:  Amy H Warriner; Ryan C Outman; Kenneth G Saag; Sarah D Berry; Cathleen Colón-Emeric; Kellie L Flood; Kenneth W Lyles; S Bobo Tanner; Nelson B Watts; Jeffrey R Curtis
Journal:  South Med J       Date:  2009-04       Impact factor: 0.954

9.  Bisphosphonate use and subsequent hip fracture in South Korea.

Authors:  Y-K Lee; Y-C Ha; H J Choi; S Jang; C Park; Y-T Lim; C S Shin
Journal:  Osteoporos Int       Date:  2013-05-17       Impact factor: 4.507

Review 10.  Excess mortality following hip fracture: a systematic epidemiological review.

Authors:  B Abrahamsen; T van Staa; R Ariely; M Olson; C Cooper
Journal:  Osteoporos Int       Date:  2009-05-07       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.